2026 Summer Intern, MBA Finance Associates Program at Bristol-Myers Squibb

Princeton, New Jersey, United States

Apply Now

Not SpecifiedCompensation

InternshipExperience Level

InternshipJob Type

UnknownVisa

PharmaceuticalsIndustries

Requirements

Minimum Qualifications:
Currently enrolled Master’s in Business Administration student, on track to graduate by Spring 2027, from an accredited institution
All candidates must be authorized to work in the US at the time of hire (no immigration or visa sponsorship available)
Proven capability to effectively communicate within work and/or academic environments, with the ability to adapt messages to suit various audiences
Preferred Qualifications:
3 to 5 years’ work experience and strong intellectual, financial and analytical skills with demonstrated ability to quickly grasp new and complex concepts
Ability to influence others and work effectively in a matrix organization
Leadership potential, with a commitment to integrity, professionalism and teamwork
Superior financial modeling skills, specifically in Excel, and the ability to quickly learn financial/accounting software
Strong time management skills, including the ability to work autonomously and within a team

Responsibilities

Development of operating budgets
R&D portfolio allocations
Financial forecasting for developmental compounds
Analysis of operating performance
Evaluation of returns on capital expenditures
Receive guidance from finance leaders
Participate in professional development workshops
Establish a strong professional network throughout the organization

Skills

Financial Forecasting

Budget Development

R&D Portfolio Allocation

Operating Performance Analysis

Capital Expenditure Evaluation

Financial Analysis

ROI Analysis

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free